Document:

Exhibit 10.4

 

Portions herein identified by [*****] have been omitted pursuant
to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of
this document has been filed separately with the Securities and Exchange Commission.

 

DATED 24th April 2013 ('Agreement
Date')

 

		(1)	AmpliPhi Bioscience Corporation

 

		(2)	The University of Leicester

 

 

COLLABORATION AGREEMENT

 

 

    	 

    	 

    

 

Portions herein identified by [*****] have been omitted pursuant
to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of
this document has been filed separately with the Securities and Exchange Commission.

 

CONTENTS

 

	1	Interpretation and Defined Terms in this Agreement	1
	 	 	 
	2	Research Work	2
	 	 	 
	3	Reports and Conferences	2
	 	 	 
	4	Costs, Billings and other Support	2
	 	 	 
	5	Publicity	3
	 	 	 
	6	Confidentiality	3
	 	 	 
	7	Publications	4
	 	 	 
	8	Intellectual Property	4
	 	 	 
	9	Grant of Rights	5
	 	 	 
	10	Term and Termination	5
	 	 	 
	11	Independent Contractor	6
	 	 	 
	12	Liabilities	6
	 	 	 
	13	Third Party Rights	7
	 	 	 
	14	Entire Agreement.	7
	 	 	 
	15	Force Majeure	7
	 	 	 
	16	Assignment	7
	 	 	 
	17	Variation	7
	 	 	 
	18	Severability	7
	 	 	 
	19	Waiver	8
	 	 	 
	20	Notices	8
	 	 	 
	21	Disputes	8
	 	 	 
	22	Governing Law	9

 

    	 

    	 

    

 

Portions herein identified by [*****] have been omitted pursuant
to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of
this document has been filed separately with the Securities and Exchange Commission.

 

COLLABORATION
AGREEMENT

 

(the 'Agreement')

 

BETWEEN:

 

		(1)	AmpliPhi Bioscience Corporation, having offices at A.B.N. 51 102 575 511, PO Box 421, Brookvale
NSW 2100 Australia, Colworth Science Park, Sharnbrook Bedfordshire, MK44 1LQ, United Kingdom and the Virginia Biotech Park, 800
Leigh St Richmond VA USA ("APHB") (the 'Sponsor'); and

 

		(2)	The University of Leicester of University Road, Leicester LE1 7RH, United Kingdom ('Leicester').

 

Each a 'Party' and together the 'Parties'.

 

INTRODUCTION

 

		(A)	Leicester through its employee Dr Martha Clokie has materials and know-how for use in the study
of bacteriophage specific for C. difficile.

 

		(B)	AmpliPhi wish to develop a phage therapeutic to resolve C. difficile infections and are funding
Leicester to carry out development work.

 

AGREED

 

		1	Interpretation and Defined Terms in this Agreement

 

In this Agreement, the terms
set out below will have the following meanings:-

 

		1.1	'Arising IP' means all (or any part) of the IP written, originated, conceived or made in the conduct of the Project by, or
on behalf of, or jointly with Leicester.

 

		1.2	'Background IP' means:-

 

		1.2.1	any IP owned by either Party at the start of the Project; and

 

		1.2.2	any specific IP necessary to the Project which the owning Party agrees in writing to make available.

 

		1.3	'Confidential Information' means any commercial, technical and other information and data (of whatever nature and form) proprietary
to the Party disclosing it (the 'Disclosing Party') which is directly or indirectly disclosed or made available by or on behalf
of the Disclosing Party to the other Party (the 'Receiving Party'), whether in writing, orally, in drawings, by site visits, by
access to computer software or data or in any other manner.

 

		1.4	'Contract Period' means from 24th April 2013 until 12th November 2014.

 

		1.5	'Costs' means the contribution of the Sponsor to the costs of the Project as set out in Annex 2.

 

    	- 1 -

    	 

    

 

Portions herein identified by [*****] have been omitted pursuant
to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of
this document has been filed separately with the Securities and Exchange Commission.

 

		1.6	'Intellectual Property' and 'IP' means all patents, registered designs, trademarks and service marks (whether registered or
not), copyright, database rights, plant breeders rights, design right, know-how, information and all similar property including
that subsisting (in any part of the world) in inventions, designs, performances, computer programs, semiconductor topographies,
confidential information, business names, goodwill and the styles of presentation of goods or services and in applications for
protection of them in any jurisdiction.

 

		1.7	'Principal Investigator' means Dr Martha Clokie (or such other employee or employees of Leicester as the Parties reasonably
agree).

 

		1.8	'Project' means the project as described in Annex 1 under the direction of the Principal Investigator.

 

		1.9	'Results' means any results generated by or on behalf of a Party under the Project including materials, data and information
and other outputs in any format.

 

		1.10	References to 'including' in this Agreement in the context of a list or description of items shall be construed as meaning
'including without limiting the generality of the foregoing', such that the items following are merely examples of items which
are included and/or items which are identified as being included for the avoidance of any doubt as to their inclusion, and such
items are not descriptive of the class of items which may be included.

 

		1.11	The headings in this Agreement are for ease of reference only and shall not affect its interpretation.

 

		2	Research Work

 

		2.1	Leicester will start to perform the Project promptly after the commencement date of the Contract Period and will use its reasonable
endeavours to perform the Project substantially in accordance with Annex 1. The Sponsor acknowledges that the Project is research
based and experimental in nature and as such, specific results cannot be guaranteed.

 

		3	Reports and Conferences

 

		3.1	Leicester will submit a final report to the Sponsor within three (3) months of:-

 

		3.1.1	the end of the Contract Period; or if earlier

 

		3.1.2	the termination of this Agreement.

 

		3.2	During the term of this Agreement, representatives of Leicester will meet or otherwise communicate with representatives of
the Sponsor at agreed times and places to discuss the progress and Results, ongoing plans and proposed changes in the Project.
In addition to the Costs, the Sponsor will pay travel costs reasonably incurred by Principal Investigators or other Leicester representatives
as may be required to attend such meetings with representatives of the Sponsor.

 

		4	Costs, Billings and other Support

 

		4.1	Leicester will invoice the Sponsor, in pounds Stel1ing, quarterly in advance, for the costs outlined in Appendix 2, except
that any costs incurred under Clause 3.2 will be paid in arrears.

 

    	- 2 -

    	 

    

 

Portions herein identified by [*****] have been omitted pursuant
to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of
this document has been filed separately with the Securities and Exchange Commission.

 

		4.2	The Costs will be paid by the Sponsor within 28 days of the date of Leicester's invoice. The Sponsor will also pay VAT at the
prevailing rate, if applicable.

 

		4.3	If the Sponsor fails to pay any Costs on the due date, Leicester may, without prejudice to its other rights and remedies, charge
the Sponsor interest in respect of the sum overdue in accordance with The Late Payment of Commercial Debts (Interest) Act 1998
from the due date for payment to the date of actual payment (both dates inclusive) and Leicester will be entitled to reimbursement
of all expenses (including legal fees) incurred with respect to collection of overdue Costs.

 

		4.4	The Sponsor shall provide support and contribute to the Project as set out in Annex 1. Leicester shall not be liable for any
delay or non-performance of its obligations hereunder where such delay or non-performance is as a result of the Sponsor's failure
to provide its support or contribution.

 

		5	Publicity

 

		5.1	The Sponsor will not use the name of Leicester, nor of any member of Leicester's Project staff, in any publicity, advertising
or news release without the prior written approval of an authorised representative of Leicester. Other than for annual reporting
purposes, Leicester will not use the name of the Sponsor, nor any employee of the Sponsor, in any publicity without the prior written
approval of the Sponsor. Notwithstanding the foregoing, Sponsor may disclose any information, including the name of Leicester,
required to be disclosed under applicable laws or regulations, including regulations of the United States Securities and Exchange
Commission or any applicable stock exchange.

 

		6	Confidentiality

 

		6.1	Each Party will not during the Agreement and for a period of three (3) years after the date of termination of this Agreement
disclose the other Party's Confidential Information.

 

		6.2	Leicester will treat Arising IP and the Results as Confidential Information of the Sponsor and, except as set forth in Clause
7, shall obtain the prior written consent of the Sponsor before disclosing the same to any third party, such consent not to be
unreasonably withheld or delayed.

 

		6.3	The obligations in Clauses 6.1 and 6.2 shall not apply or shall cease to apply to Confidential Information which:

 

		6.3.1	has been received from a third party who are not bound by an obligation of confidentiality to the Disclosing Party;

 

		6.3.2	was already in the Receiving Party's possession prior to its acquisition from the Disclosing Party as evidenced by written
records;

 

		6.3.3	was independently generated by the Receiving Party as evidenced by written records;

 

		6.3.4	is in or comes into the public domain other than by reason of a breach of this Agreement;

 

		6.3.5	is required to be disclosed by law or a court or other competent authority including, but not limited to, disclosures required
under the Freedom of Information Act 2000, the Freedom of Information (Scotland) Act 2002 and the Environmental Information Regulations
2004; or

 

    	- 3 -

    	 

    

 

Portions herein identified by [*****] have been omitted pursuant
to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of
this document has been filed separately with the Securities and Exchange Commission.

 

		6.3.6	is disclosed with prior written consent of the Disclosing Party.

 

		7	Publications

 

		7.1	The Sponsor recognises that Leicester staff will normally wish to publish the Results and/or Arising IP. Leicester will:

 

		7.1.1	provide to Sponsor a draft of any proposed paper or article at least 30 days prior to its submission for publication; and

 

		7.1.2	provide a draft of any proposed oral presentation to the Sponsor at least 30 days prior to the date of the oral presentation;
and

 

		7.1.3	acknowledge all contributors to the Results and/or Arising IP within the paper, article and/or presentation.

 

		7.2	Within 30 days of the date of provision to the Sponsor under Clause 7.1, the Sponsor may in writing:-

 

		7.2.1	notify Leicester of its approval; or

 

		7.2.2	request reasonable amendments to protect the Sponsor's commercial interests; and/or

 

		7.2.3	request a reasonable delay to publication (limited to a maximum of 30 days from the date of receipt of the Sponsor's response)
to the extent required to file patent applications in such Arising IP.

 

		7.3	If Leicester receives no notification under Clause 7.2 within 30 days of the date of provision to the Sponsor, the Sponsor
will be deemed to have given approval. Leicester will comply with any reasonable requests provided timely pursuant to Clause 7.2.

 

		7.4	The Sponsor will not publish the Results and/or Arising IP without the prior written consent of Leicester, such consent at
Leicester's sole discretion but not to be unreasonably withheld.

 

		8	Intellectual Property

 

		8.1	For the avoidance of doubt all Background IP used in connection with the Project shall remain the property of the Party to
whom it belonged prior to the commencement of the Project.

 

		8.2	All rights to Arising IP under the Project shall belong in the first instance to the Sponsor. Leicester hereby assigns to Sponsor
all right, title and interest to any Arising IP.

 

		8.3	The Sponsor may, at its sole cost, apply for patent or other IP protection in the Sponsor's name for any Arising IP. Leicester
will cooperate with the Sponsor in executing such documents as may be reasonably required in the prosecution of such application(s).

 

    	- 4 -

    	 

    

 

Portions herein identified by [*****] have been omitted pursuant
to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of
this document has been filed separately with the Securities and Exchange Commission.

 

		8.4	The Sponsor will pay all reasonable costs incurred by Leicester for any assistance that Leicester provides to the Sponsor in
respect of Clause 8.3 and/or in support of any application for patent or other IP protection.

 

		8.5	The Sponsor will not allow to lapse its rights to apply for protection of or prosecution or maintenance of the protection of
the Arising IP without first notifying Leicester in writing of its intention not to apply for protection of or prosecution or maintenance
of the protection of the Arising IP and without offering such rights to Leicester free of charge. Leicester will then be free to
file or continue prosecution or maintain any such application(s) and to maintain any protection in any jurisdiction at Leicester's
sole expense.

 

		8.6	The Sponsor will grant to Leicester a perpetual, non-exclusive, sub-licensable, royalty free licence to use the Arising IP
and the Results for academic research and teaching purposes.

 

		9	Grant of Rights

 

		9.1	The Sponsor grants to Leicester a non-exclusive, sub-licensable, royalty-free licence to use the Arising IP and Results to
the extent necessary for the purposes of the Project.

 

		9.2	The Parties grant to each other a royalty-free right to use each other's Background IP to the extent required for the purpose
of the Project (during the Contract Period only) and subject to any third party rights to such Background IP.

 

		9.3	If the Sponsor requires access to Background IP owned by Leicester, Leicester expresses its willingness to grant a separate
non-exclusive licence:

 

		9.3.1	only to the extent required to commercialise the Results and/or Arising IP;

 

		9.3.2	upon fair and reasonable commercial terms to be agreed; and

 

		9.3.3	subject to any third party rights to such Background IP.

 

		10	Term and Termination

 

		10.1	This Agreement will continue until the end of the Contract Period unless terminated in accordance with this Clause 10 or by
mutual written agreement of the Parties.

 

		10.2	Either Party may terminate this Agreement on written notice forthwith, if:

 

		10.2.1	the other Party commits a material breach of this Agreement which has not been remedied after 90 days written notice of the
breach (such notice expressly referring to possible termination of this Agreement); or

 

		10.2.2	the Principal Investigator becomes unable or unwilling to continue the Project, and a mutually acceptable substitute is not
available (such an event not to be treated as a breach of this Agreement).

 

		10.3	Leicester may terminate this Agreement forthwith if the Sponsor enters into any arrangement or composition with its creditors,
commits any act of bankruptcy or (being a corporation) if an order is made or an effective resolution is passed for its winding
up (except for the purposes of amalgamation or reconstruction), or if a petition is presented to court, or if a receiver and manager,
receiver, administrative receiver or administrator is appointed in respect of the whole, or any part of, the Sponsor's undertaking
or assets or there are reasonable grounds for anticipating the occurrence of any of these events within the foreseeable future.

 

    	- 5 -

    	 

    

 

Portions herein identified by [*****] have been omitted pursuant
to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of
this document has been filed separately with the Securities and Exchange Commission.

 

		10.4	On termination of this Agreement (except for termination by the Sponsor under Clause 10.2.1) the Sponsor will pay all Costs
falling due for payment prior to termination and any non-cancellable costs incurred after the date of termination arising from
commitments reasonably incurred and/or entered into by Leicester in connection with the performance of the Project prior to the
date of termination.

 

		10.5	Subject to Clause 8, termination of the Agreement by either Party for any reason shall not affect the rights and obligations
of the Parties accrued prior to the effective date of termination of this Agreement. No termination of this Agreement, for any
reason, shall affect the Sponsor's rights and duties under Clause 8. Those clauses of this Agreement which are expressly or impliedly
intended to continue after termination shall continue in effect after termination. Clauses 4, 6 and 8 and 9 will expressly continue
after the termination of this Agreement.

 

		11	Independent Contractor

 

		11.1	In the performance of the Project under this Agreement Leicester shall be deemed to be and shall be an independent contractor
and, as such, Leicester will not be entitled to any benefits applicable to employees of the Sponsor.

 

		11.2	Neither Party is authorised or empowered to act as agent for the other for any purpose and shall not on behalf of the other
enter into any contract, warranty, or representation as to any matter. Neither shall be bound by the acts or conduct of the other.

 

		12	Liabilities

 

		12.1	Notwithstanding any other provisions in this Agreement, nothing in this Agreement shall exclude or limit either Party's liability
for the following:

 

		12.1.1	death or personal injury resulting from negligence;

 

		12.1.2	fraud or statements made fraudulently;

 

		12.1.3	any other acts or omissions for which the governing law prohibits the exclusion or limitation of liability.

 

		12.2	Save as provided in Clause 12.1, Leicester will not be liable for any loss of profit, loss of business, loss of goodwill, loss
of savings, claims by third parties, loss of anticipated savings, indirect loss or consequential loss whatsoever and howsoever
caused (even if caused by Leicester's negligence and/or breach of contract and even if Leicester was advised that such loss would
probably result).

 

		12.3	Subject to Clause 12.1 of this Agreement, Leicester's total liability for any claims, losses, damages or expenses whatsoever
and howsoever caused (even if caused by Leicester's negligence and/or breach of contract) shall be limited for each event or series
of linked events as follows:

 

		12.3.1	in relation to liability arising out of a breach or negligence in connection with this Agreement to a maximum sum equal to
the total Costs payable by the Sponsor to Leicester under the Agreement, or £200,000, whichever is the greater;

 

    	- 6 -

    	 

    

 

Portions herein identified by [*****] have been omitted pursuant
to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of
this document has been filed separately with the Securities and Exchange Commission.

 

		12.3.2	in relation to liability outside the scope of Clause 12.3.1, to £200,000.

 

		12.4	Whilst Leicester will use all reasonable endeavours to ensure the accuracy of the work performed and any information and Results
given, Leicester makes no warranty, express or implied, as to accuracy and, subject to Clause 12.1 will not be held responsible
for any consequence arising out of any inaccuracies or omissions unless such inaccuracies or omissions are the result of Leicester's
negligence.

 

		12.5	The Sponsor acknowledges that the nature of the Project is research based and the application of any Results will not be thoroughly
tested. Accordingly, subject to Clause 12.1, Leicester will not be liable for any claims, losses, damages or expenses whatsoever
and howsoever caused arising out of any use (or interpretation) by the Sponsor or any other party of the Results (or any product
or process generated out of them). notwithstanding that the formulation of such product or process may be based upon the Results.

 

		13	Third Party Rights

 

		13.1	The Parties to this Agreement do not intend that any of its terms will be enforceable by virtue of the Contracts (Rights of
Third Parties) Act 1999 by any person not a Party to it.

 

		14	Entire Agreement

 

		14.1	Each Party acknowledges that this Agreement contains the whole agreement between the Parties in respect of its subject matter
and supersedes all prior arrangements, agreements and understandings between them relating to the subject matter.

 

		15	Force Majeure

 

		15.1	Any failure or delay by either Party in the performance of its obligations pursuant to this Agreement which is due to a force
majeure event will not be deemed a default of this Agreement or a ground for termination.

 

		16	Assignment

 

		16.1	This Agreement shall not be assigned by either Party without the prior written consent of the other, such consent not to be
unreasonably withheld or delayed. Notwithstanding the foregoing, Sponsor may assign this Agreement in connection with any merger,
consolidation or sale of all or substantially all of the assets of Sponsor to which this Agreement relates.

 

		17	Variation

 

		17.1	Any variation to this Agreement (and/or the Project) shall be in writing and signed by authorised signatories for both Parties.

 

		18	Severability

 

		18.1	If any provision of this Agreement is declared void or unenforceable, such provision shall be severed from this Agreement,
which shall otherwise remain in full force and effect.

 

    	- 7 -

    	 

    

 

Portions herein identified by [*****] have been omitted pursuant
to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of
this document has been filed separately with the Securities and Exchange Commission.

 

		19	Waiver

 

		19.1	No failure, delay relaxation or indulgence on the part of either Party in exercising or partial exercise of any right hereunder
shall operate as a waiver of such rights.

 

		20	Notices

 

		20.1	Any notice, demand or communication in connection with this Agreement will be in writing and may be delivered by hand, first
class post, Special Delivery post but not by email addressed to the recipient below (or another person which the recipient has
notified in writing to the sender in accordance with this Clause 20.1, to be received by the sender not less than seven days before
the notice is despatched).

 

		20.1.1	For Leicester- to Enterprise and Business Development Office, University of Leicester, University Road, Leicester, LE1 7RH,
United Kingdom

 

		20.1.2	For the Sponsor- to Philip J Young, CEO AmpliPhi Biosciences 800 E. Leigh St Richmond, VA 23219

 

		20.2	The notice, demand or communication will be deemed to have been duly served:

 

		20.2.1	if delivered by hand, at the time of delivery;

 

		20.2.2	if delivered by first class post or Special Delivery post, 48 hours after being posted (excluding days other than business
days in England).

 

		20.3	The contacts for academic issues and day to day management of the Project will be:-

 

		20.3.1	For Leicester:- Dr Martha Clokie, Dept Infection, Immunity & Inflammation, University of Leicester, Maurice Shock Medical
Sciences Building, University Road, Leicester, LE1 9HN, United Kingdom

 

		20.3.2	For the Sponsor:- Philip J Young, CEO AmpliPhi Biosciences 800 E. Leigh St Richmond, VA 23219

 

		21	Disputes

 

		21.1	All disputes will initially be referred by either Party to a representative of each Party responsible for the overall performance
of this Agreement, who will meet as soon as reasonably practicable to discuss the dispute. If those representatives are unable
to resolve the dispute after meeting, the dispute shall be referred to the Managing Director of the Sponsor and the Director of
the Enterprise and Business Development Office of Leicester. The Directors will meet within 20 working days and attempt to resolve
the dispute.

 

		21.2	If any dispute arises out of this Agreement which the Directors are unable to resolve within 5 working days of their meeting
pursuant to Clause 21.1, the Parties will attempt to settle it by mediation in accordance with the Centre for Dispute Resolution
(CEDR) Model Mediation Procedure.

 

		21.3	To initiate a mediation a Party must give notice in writing to the other Party requesting a mediation (the 'ADR Notice') and
send a copy of the ADR Notice to CEDR.

 

    	- 8 -

    	 

    

 

Portions herein identified by [*****] have been omitted pursuant
to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of
this document has been filed separately with the Securities and Exchange Commission.

 

		21.4	If there is any point in the conduct of the mediation (including nomination of the mediator) upon which the Parties cannot
agree within 14 days from the date of the ADR Notice, CEDR will, at the request of either Party, decide that point for the Parties,
having consulted with them.

 

		21.5	The mediation will start not later than 28 days after the date of the ADR Notice.

 

		21.6	Neither Party may commence any court proceedings in relation to any dispute arising out of this Agreement until they have attempted
to settle it by mediation and such attempt has been unsuccessful, provided that nothing in this Agreement will prevent either Party

 

		21.7	seeking injunctive relief to prevent or stay a breach of any provision of this Agreement.

 

		22	Governing Law

 

		22.1	This Agreement is governed by English law and the Parties submit to the exclusive jurisdiction of the courts of England and
Wales.

 

    	- 9 -

    	 

    

 

Portions herein identified by [*****] have been omitted pursuant
to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of
this document has been filed separately with the Securities and Exchange Commission.

 

Annex 1

 

The Project

 

'Development of Phage for the treatment
of C. dlfficile infections'

 

Leicester's contribution to the Project

 

Project program

 

Product identification – identify and obtain relevant
clinical isolates

 

Qualify C. difficile manufacturing hosts – temperate
phage, toxins, sporulation

 

Product manufacture – process development and transfer
to GMP

 

Phage stocks – prepare and screen 26 phage against
key C. difficile ribotypes

 

Selection of candidate phage – propagate selected phage
in selected hosts and prepare lysates of candidate combinations

 

Dr Janet Nale will fulfil the role of Postdoctoral Research
assistant for the project.

 

Dr Martha Clokie will provide 2 days of consultancy a
month, at a rate of £720 per day, to support the project.

 

Sponsor's contribution to the Project

 

In addition to funding the work, AmpliPhi will provide advice
throughout the project through regular telecons, e-mails and meetings.

 

    	- 10 -

    	 

    

 

Portions herein identified by [*****] have been omitted pursuant
to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of
this document has been filed separately with the Securities and Exchange Commission. 

 

Annex 2

 

Financial

 

[*****]

 

    	- 11 -

    	 

    

 

Portions herein identified by [*****] have been omitted pursuant
to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of
this document has been filed separately with the Securities and Exchange Commission.

 

	Signed	 	 	Signed	 
	 	 	 	 	 
	Authorised Signature for and on behalf of Sponsor	 	Authorised Signature for and on behalf of Leicester
	 	 	 	 	 
	Name	Philip J. Young	 	Name	Dr Chris Jones
	 	 	 	 	 
	Position	President & CEO	 	Position	Head of Research Commercialisation
	 	 	 	 	 
	Dated	 	 	Dated	 

 

    	- 12 -Exhibit 10.5

 

Portions herein identified by [*****] have been omitted pursuant
to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of
this document has been filed separately with the Securities and Exchange Commission.

 

	DATED 1st August 2013 (‘Agreement Date’)

 

		(1)	AmpliPhi Bioscience Corporation

		(2)	The University of Leicester

		(3)	The University of Glasgow

 

 

 

COLLABORATION AGREEMENT

 

 

 

    	 

    	 

    

 

Portions herein identified by [*****] have been omitted pursuant
to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of
this document has been filed separately with the Securities and Exchange Commission.

 

CONTENTs

 

	1	Interpretation and Defined Terms in this Agreement	2
	 	 	 
	2	Research Work	3
	 	 	 
	3	Reports and Conferences	3
	 	 	 
	4	Costs, Billings and other Support	3
	 	 	 
	5	Publicity	4
	 	 	 
	6	Confidentiality	4
	 	 	 
	7	Publications	5
	 	 	 
	8	Intellectual Property	5
	 	 	 
	9	Grant of Rights	6
	 	 	 
	10	Term and Termination	7
	 	 	 
	11	Independent Contractor	8
	 	 	 
	12	Liabilities	8
	 	 	 
	13	Third Party Rights	10
	 	 	 
	14	Entire Agreement	10
	 	 	 
	15	Force Majeure	10
	 	 	 
	16	Assignment	10
	 	 	 
	17	Variation	10
	 	 	 
	18	Severability	10
	 	 	 
	19	Waiver	11
	 	 	 
	20	Notices	11
	 	 	 
	21	Disputes	11
	 	 	 
	22	Governing Law	11

 

    	 

    	 

    

 

Portions herein identified by [*****] have been omitted pursuant
to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of
this document has been filed separately with the Securities and Exchange Commission.

 

COLLABORATION
AGREEMENT

 

(the ‘Agreement’) Dated 1st
August 2013

 

Between:

 

		(1)	AmpliPhi Bioscience Corporation, having offices at A.B.N. 51 102 575 511, PO Box 421, Brookvale
NSW 2100 Australia, Colworth Science Park, Sharnbrook Bedfordshire, MK44 1LQ, United Kingdom and 4870 Sadler Rd Suite 300, Glen
Allen, VA 23060 USA (the “Sponsor”); and

 

		(2)	The University of Leicester of University Road, Leicester LE1 7RH, United Kingdom (“Leicester”);
and

 

		(3)	The University Court of the University of Glasgow, incorporated under the Universities (Scotland)
Act 1889 and having its principal office at University Avenue, Glasgow G12 8QQ, United Kingdom a registered Scottish charity in
terms of Section 13(2) of the Charities and Trustee Investment (Scotland) Act 2005 (Charity Number SC004401, Charity Name ‘University
of Glasgow Court’) (“Glasgow”).

 

Each a ‘Party’ and together
the ‘Parties’.

 

INTRODUCTION

 

		(A)	Leicester through its employee Dr Martha Clokie has Materials, Intellectual Property [*****] and know-how for use in the development
of bacteriophage specific for C. difficile for use as therapeutic agents against Clostridium difficile (C. difficile) infections.

 

		(B)	Glasgow through its employee Dr Gill Douce has expertise and know-how in animal models of C. difficile infection.

 

		(C)	Sponsor wishes to develop a bacteriophage therapeutic to resolve C. difficile infections and are funding Leicester (to carry
out in vitro) and Glasgow (to carry out animal model) development work on Leicester’s bacteriophage.

 

		(D)	This Agreement covers the work programme to be carried out at Glasgow; Leicester will provide the bacteriophage and act as
overall Project Coordinator for the development work; including project managing (ensuring the timely provision of Leicester’s
Materials and regular communication) and coordinating the reporting of data to Sponsor and ensuring that results are presented
in a translatable form. The funding of Leicester’s in vitro work programme is the subject of a separate collaboration agreement
between Leicester and Sponsor dated April 24th, 2013, (the “Collaboration Agreement”).

 

    	- 1 -

    	 

    

 

Portions herein identified by [*****] have been omitted pursuant
to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of
this document has been filed separately with the Securities and Exchange Commission.

 

Agreed

 

		1	Interpretation and Defined Terms in this Agreement

 

In this Agreement, the terms set out below will
have the following meanings:-

 

		1.1	‘Arising IP’ means all (or any part) of the IP written, developed, originated, conceived or made in the conduct
of the Project by, or on behalf of, or jointly with Glasgow and/or Leicester, specifically including any Results but excluding
Glasgow’s Background IP and any Improvements.

 

		1.2	‘Background IP’ means any IP:-

 

		1.2.1	owned by any Party at the start of Contract Period; and

 

		1.2.2	necessary to the Project which the owning Party agrees in writing to make available for use in the Project (as such use may
be agreed to by the Sponsor);

 

		1.3	‘Confidential Information’ means any commercial, technical and other information and data (of whatever nature and
form) proprietary to the Party disclosing it (the ‘Disclosing Party’) which is directly or indirectly disclosed or
made available by or on behalf of the Disclosing Party to the other Party (the ‘Receiving Party’), whether in writing,
orally, in drawings, by site visits, by access to computer software or data or in any other manner.

 

		1.4	‘Contract Period’ means from 1st August, 2013 until 22nd October, 2014.

 

		1.5	‘Costs’ means the contribution of the Sponsor to the costs of the Project as set out in Annex 2.

 

		1.6	‘Improvements’ means any improvements, modifications, adaptations to or new uses or applications of Glasgow’s
Background IP.

 

		1.7	‘Intellectual Property’ and ‘IP’ means all patents, registered designs, trademarks and service marks
(whether registered or not), copyright, database rights, plant breeders rights, design right, know-how, information and all similar
property and rights including that subsisting (in any part of the world) in inventions, designs, performances, computer programs,
semiconductor topographies, confidential information, business names, goodwill and the styles of presentation of goods or services
and in applications for protection of them in any jurisdiction.

 

		1.8	‘Leicester’s Materials’ means Leicester’s C. difficile specific bacteriophage in Leicester’s
possession prior to the start of the Contract Period.

 

		1.9	‘Principal Investigator’ means Dr Gill Douce (or such other employee or employees of Glasgow as the Parties reasonably
agree).

 

		1.10	‘Project’ means the project as described in Annex 1 under the direction of the Principal Investigator.

 

		1.11	‘Project Coordinator’ means Leicester. The tasks of the Project Coordinator will be carried out by Dr Martha Clokie
and will include ensuring the timely provision of Leicester’s Materials, scheduling regular Project updates and meetings,
collating data, ensuring that Results are presented in a translatable form and submitting reports to Sponsor.

 

    	- 2 -

    	 

    

 

Portions herein identified by [*****] have been omitted pursuant
to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of
this document has been filed separately with the Securities and Exchange Commission.

 

		1.12	‘Results’ means any results generated by or on behalf of a Party under the Project including materials, data and
information and other outputs in any format.

 

		1.13	References to ‘including’ in this Agreement in the context of a list or description of items shall be construed
as meaning ‘including without limiting the generality of the foregoing’, such that the items following are merely examples
of items which are included and/or items which are identified as being included for the avoidance of any doubt as to their inclusion,
and such items are not descriptive of the class of items which may be included.

 

		1.14	The headings in this Agreement are for ease of reference only and shall not affect its interpretation.

 

		2	Research Work

 

		2.1	Glasgow will start to perform the Project promptly after the commencement date of the Contract Period and will use its reasonable
endeavours to perform the Project substantially in accordance with Annex 1. The Sponsor acknowledges that the Project is research
based and experimental in nature and as such, specific results cannot be guaranteed.

 

		2.2	Leicester will provide Leicester’s Materials to Glasgow within forty-five (45) days of the start of the Contract Period
as required for the Project.

 

		3	Reports and Conferences

 

		3.1	Glasgow will submit a final report to Leicester and Sponsor within forty-five (45) days following:-

 

		3.1.1	the end of the Contract Period; or if earlier

 

		3.1.2	the termination of this Agreement.

 

		3.2	Leicester and Sponsor will then coordinate the delivery of the final report to Sponsor within one month of receipt of the final
report from Glasgow.

 

		3.3	During the term of this Agreement, representatives of Glasgow and Leicester will meet or otherwise communicate with representatives
of the Sponsor at agreed times and places to discuss progress and the Results, ongoing plans and proposed changes in the Project.
In addition to the Costs, the Sponsor will pay travel costs reasonably incurred by the Principal Investigator or other Glasgow
or Leicester representatives as may be required to attend such meetings with representatives of the Sponsor.

 

		4	Costs, Billings and other Support

 

		4.1	Glasgow will invoice the Sponsor, in pounds Sterling, in advance, for the Costs according to the payment plan in Annex 2, except
that any costs incurred under Clause 3.3 will be paid in arrears.

 

		4.2	The Costs will be paid by the Sponsor within 28 days of the date of Glasgow’s invoice. The Sponsor will also pay
VAT at the prevailing rate, if applicable.

 

    	- 3 -

    	 

    

 

Portions herein identified by [*****] have been omitted pursuant
to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of
this document has been filed separately with the Securities and Exchange Commission.

 

		4.3	If the Sponsor fails to pay any Costs on the due date, Glasgow may, without prejudice to its other rights and remedies, charge
the Sponsor interest in respect of the sum overdue in accordance with The Late Payment of Commercial Debts (Interest) Act 1998
from the due date for payment to the date of actual payment (both dates inclusive) and Glasgow will be entitled to reimbursement
of all expenses (including legal fees) incurred with respect to collection of overdue Costs.

 

		4.4	The Sponsor shall provide support and contribute to the Project as set out in Annex 1. Glasgow shall not be liable for any
delay or non-performance of its obligations hereunder where such delay or non-performance is as a result of the Sponsor’s
failure to provide its support or contribution.

 

		4.5	Any costs incurred by Leicester in the performance of the Project Coordinator role will be covered under the Collaboration
Agreement.

 

		5	Publicity

 

		5.1	The Sponsor will not use the name of Glasgow or Leicester, nor of any member of Glasgow's or Leicester’s Project staff,
in any publicity, advertising or news release without the prior written approval of an authorised representative of Glasgow or
Leicester. Other than for annual reporting purposes, Glasgow and Leicester will not use the name of the Sponsor, nor any employee
of the Sponsor, in any publicity without the prior written approval of the Sponsor. Notwithstanding the foregoing, Sponsor may
disclose any information, including the name of Glasgow or Leicester, required to be disclosed under applicable laws or regulations,
including regulations of the United States Securities and Exchange Commission or any applicable stock exchange.

 

		6	Confidentiality

 

		6.1	Each Party will not during the Agreement and for a period of five (5) years after the date of termination of this Agreement
disclose Confidential Information of either of the other Parties.

 

		6.2	Glasgow and Leicester will treat Arising IP and the Results as Confidential Information of the Sponsor and, except as set forth
in Clause 7, shall obtain the prior written consent of the Sponsor before disclosing the same to any third party, such consent
not to be unreasonably withheld or delayed. The Parties expressly agree that it shall be reasonable for the Sponsor to withhold
such consent if in Sponsor’s discretion any such disclosure would limit Sponsor’s ability to protect such Arising IP.

 

		6.3	The obligations in Clauses 6.1 and 6.2 shall not apply or shall cease to apply to Confidential Information which:

 

		6.3.1	has been received from a third party who are not bound by an obligation of confidentiality to the Disclosing Party;

 

		6.3.2	was already in the Receiving Party’s possession prior to its acquisition from the Disclosing Party as evidenced by written
records;

 

		6.3.3	was independently generated by the Receiving Party without the use of the Disclosing Party’s Confidential Information
as evidenced by written records;

 

    	- 4 -

    	 

    

 

Portions herein identified by [*****] have been omitted pursuant
to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of
this document has been filed separately with the Securities and Exchange Commission.

 

		6.3.4	is in or comes into the public domain other than by reason of a breach of this Agreement;

 

		6.3.5	is required to be disclosed by law or a court or other competent authority including, but not limited to, disclosures required
under the Freedom of Information Act 2000, the Freedom of Information (Scotland) Act 2002 and the Environmental Information Regulations
2004; or

 

		6.3.6	is disclosed with prior written consent of the Disclosing Party.

 

		7	Publications

 

		7.1	The Sponsor recognises that Glasgow and Leicester staff will normally wish to publish the Results and/or Arising IP. Glasgow
and Leicester will:

 

		7.1.1	provide to Sponsor a draft of any proposed paper or article at least 30 days prior to its submission for publication; and

 

		7.1.2	provide a draft of any proposed oral presentation to the Sponsor at least 30 days prior to the date of the oral presentation;
and

 

		7.1.3	acknowledge all contributors to the Results and/or Arising IP within the paper, article and/or presentation.

 

		7.2	Within 30 days of the date of provision to the Sponsor under Clause 7.1, the Sponsor may in writing:-

 

		7.2.1	request reasonable amendments to protect the Sponsor’s commercial interests; and/or

 

		7.2.2	request a reasonable delay to publication (limited to a maximum of 30 days from the date of receipt of the Sponsor’s
response) to the extent required to file patent applications on such Arising IP.

 

		7.3	If Glasgow and Leicester receive no notification under Clause 7.2 within 30 days of the date of provision to the Sponsor,
the Sponsor will be deemed to have given approval. Glasgow and Leicester will comply with any reasonable requests provided timely
pursuant to Clause 7.2.

 

		7.4	During the term of this Agreement and for six (6) months thereafter, the Sponsor will not publish the Results and/or Arising
IP without the prior written consent of Glasgow and Leicester, such consent not to be unreasonably withheld or delayed, provided
that no consent shall be required for any disclosure of Results and/or Arising IP that has previously entered the public domain
other than by breach of this Agreement.

 

		8	Intellectual Property

 

		8.1	For the avoidance of doubt all Background IP and Leicester’s Materials used in connection with the Project shall remain
the property of the Party to whom it belonged prior to the commencement of the Project.

 

		8.2	All rights, title and interest to Arising IP under the Project shall belong to the Sponsor as follows:

 

    	- 5 -

    	 

    

 

Portions herein identified by [*****] have been omitted pursuant
to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of
this document has been filed separately with the Securities and Exchange Commission.

 

Glasgow’s rights, title
and interest to any Arising IP under the Project have been assigned to Leicester under a separate assignment and revenue sharing
agreement between Glasgow and Leicester (the “Revenue Sharing Agreement”). Leicester in turn shall and hereby does
assign all rights, title and interest to any Results and Arising IP including all those received under the Revenue Sharing Agreement
to the Sponsor.

 

		8.3	The Sponsor may, at its sole cost, apply for patent or other IP protection in the Sponsor's name for any Arising IP. Glasgow
and Leicester will cooperate with the Sponsor in executing such documents as may be reasonably required in the prosecution of such
application(s).

 

		8.4	The Sponsor will pay all reasonable costs incurred by Glasgow and Leicester for any assistance that Glasgow and Leicester provide
to the Sponsor in respect of Clause 8.3 and/or in support of any application for patent or other IP protection.

 

		8.5	The Sponsor will not intentionally allow to lapse its rights to apply for protection of or prosecution or maintenance of the
protection of the Arising IP without first notifying Leicester in writing of its intention not to apply for protection of or prosecution
or maintenance of the protection of the Arising IP and without offering such rights to Leicester free of charge. Leicester will
then be free to file or continue prosecution or maintain any such application(s) and to maintain any protection in any jurisdiction
at Leicester’s sole expense.

 

		8.6	The Sponsor grants to Glasgow and Leicester a perpetual, irrevocable, non-exclusive, sub-licensable, royalty-free licence to
use the Arising IP and the Results for non-commercial collaborative research with non-commercial organisations and for each entity’s
own academic research and teaching purposes.

 

		9	Grant of Rights

 

		9.1	The Sponsor grants to Glasgow and Leicester a non-exclusive, sub-licensable, royalty-free licence to use the Arising IP and
Results to the extent necessary for the purposes of the Project.

 

		9.2	The Parties grant to each other a royalty-free right to use each other’s Background IP and Leicester’s Materials
to the extent required for the purpose of the Project (during the Contract Period only) and subject to any third party rights to
such Background IP.

 

		9.3	If the Sponsor requires access to Background IP, owned by Glasgow and/or Leicester, Glasgow and/or Leicester express their
willingness to grant separate non-exclusive licences:

 

		9.3.1	only to the extent required to commercialise the Results and/or Arising IP;

 

		9.3.2	upon fair and reasonable commercial terms to be agreed; and

 

		9.3.3	subject to any third party rights to such Background IP.

 

		10	Ownership, Supply and use of Leicester’s Materials

 

		10.1	Glasgow shall not supply the whole or any part of Leicester’s Materials to any other person or organisation and nor shall
it permit any other person or organisation to make use of Leicester’s Materials.

 

    	- 6 -

    	 

    

 

Portions herein identified by [*****] have been omitted pursuant
to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of
this document has been filed separately with the Securities and Exchange Commission.

 

		10.2	Glasgow undertakes that Leicester’s Materials will only be used by Glasgow and its employees (under the direct supervision
of the Principle Investigator) for the sole purpose of the Project and will not be used for any commercial purpose or commercially
sponsored research. Glasgow will not administer any of Leicester’s Materials to humans and Leicester’s Materials will
not be used for the testing or treatment of humans or in relation to human diagnosis or care.

 

		10.3	Glasgow shall keep Leicester’s Materials at Glasgow’s premises in a safe, clean, uncontaminated and suitable environment
and use Leicester’s Materials only in accordance with best laboratory practice.

 

		10.4	Glasgow shall at all times comply with all usual precautions in handling materials of such nature and all applicable laws and
regulations applicable to the use, shipping, storage, handling or disposal of Leicester’s Materials and in particular shall
ensure that all appropriate consents have been obtained in relation to such use, shipping, storage, handling or disposal of Leicester’s
Materials.

 

		10.5	Glasgow shall take reasonable steps to ensure all its employees and all other persons engaged in the Project using Leicester’s
Materials are aware of and comply with the terms of the Agreement.

 

		11	Term and Termination

 

		11.1	This Agreement will continue until the end of the Contract Period unless terminated in accordance with this Clause 11
or by mutual written agreement of the Parties.

 

		11.2	Any Party may terminate this Agreement on written notice forthwith, if:

 

		11.2.1	Any other Party commits a material breach of this Agreement which has not been remedied after 90 days written notice of the
breach (such notice expressly referring to possible termination of this Agreement); or

 

		11.2.2	the Principal Investigator becomes unable or unwilling to continue the Project, and a mutually acceptable substitute is not
available (such an event not to be treated as a breach of this Agreement).

 

		11.3	Glasgow and Leicester may terminate this Agreement forthwith if the Sponsor enters into any arrangement or composition with
its creditors, commits any act of bankruptcy or (being a corporation) if an order is made or an effective resolution is passed
for its winding up (except for the purposes of amalgamation or reconstruction), or if a petition is presented to court, or if a
receiver and manager, receiver, administrative receiver or administrator is appointed in respect of the whole, or any part of,
the Sponsor's undertaking or assets or there are reasonable grounds for anticipating the occurrence of any of these events within
the foreseeable future.

 

		11.4	On termination of this Agreement (except for termination by the Sponsor under Clause 11.2.1) the Sponsor will pay all
Costs falling due for payment prior to termination and any non-cancellable costs incurred after the date of termination arising
from commitments reasonably incurred and/or entered into by Glasgow in connection with the performance of the Project prior to
the date of termination. The Sponsor shall pay all such Costs within thirty (30) days of the date of Glasgow’s invoice for
those Costs.

 

    	- 7 -

    	 

    

 

Portions herein identified by [*****] have been omitted pursuant
to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of
this document has been filed separately with the Securities and Exchange Commission.

 

		11.5	Subject to Clause 8, termination of the Agreement by a Party for any reason shall not affect the rights and obligations of
the Parties accrued prior to the effective date of termination of this Agreement. No termination of this Agreement, for any reason,
shall affect the Sponsor's rights and duties under Clause 8. Those clauses of this Agreement which are expressly or impliedly intended
to continue after termination shall continue in effect after termination. Clauses 4 (solely to the extent any such costs relate
to work conducted prior to the effective date of termination), 6, 8 and 9 will expressly continue after the termination of this
Agreement.

 

		12	Independent Contractor

 

		12.1	In the performance of the Project under this Agreement Glasgow and Leicester shall be deemed to be and shall be independent
contractors and, as such, Glasgow and Leicester will not be entitled to any benefits applicable to employees of the Sponsor.

 

		12.2	No Party is authorised or empowered to act as agent for another Party for any purpose and shall not on behalf of another Party
enter into any contract, warranty, or representation as to any matter. Neither shall any Party be bound by the acts or conduct
of another Party.

 

		13	Liabilities

 

		13.1	The Sponsor shall and hereby agrees to indemnify Glasgow and Leicester in full in respect of any loss, liability or damage
including but not limited to liability for death, personal injury, or damage to property and any third party claims incurred or
suffered by or imposed upon Glasgow or Leicester directly or indirectly as a result or in connection with the Project or the Sponsor’s
use, development and/or exploitation of the Arising IP.

 

		13.2	Notwithstanding any other provisions in this Agreement, nothing in this Agreement shall exclude or limit a Party’s liability
for the following:

 

		13.2.1	death or personal injury resulting from negligence;

 

		13.2.2	fraud or statements made fraudulently;

 

		13.2.3	any other acts or omissions for which the governing law prohibits the exclusion or limitation of liability.

 

		13.3	Save as provided in Clause 13.1 or 13.2, No Party will be liable for any loss of profit, loss of business, loss of goodwill,
loss of savings, claims by third parties, loss of anticipated savings, indirect loss or consequential loss whatsoever and howsoever
caused (even if caused by such Party’s negligence and/or breach of contract and even if such Party was advised that such
loss would probably result).

 

		13.4	Subject to Clause 13.2 of this Agreement, Glasgow’s total liability for any claims, losses, damages or expenses whatsoever
and howsoever caused (even if caused by Glasgow’s negligence and/or breach of contract) shall be limited for each event or
series of linked events as follows:

 

		13.4.1	in relation to liability arising out of a breach or negligence in connection with this Agreement to a maximum sum equal to
the total Costs payable by the Sponsor to Glasgow under the Agreement, or £100,000, whichever is the greater;

 

    	- 8 -

    	 

    

 

Portions herein identified by [*****] have been omitted pursuant
to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of
this document has been filed separately with the Securities and Exchange Commission.

 

		13.4.2	in relation to liability outside the scope of Clause 13.4.1, to £100,000.

 

		13.5	Subject to Clause 13.2 of this Agreement, Leicester’s total liability for any claims, losses, damages or expenses whatsoever
and howsoever caused (even if caused by Leicester’s negligence and/or breach of contract) shall be limited for each event
or series of linked events as follows:

 

		13.5.1	in relation to liability arising out of a breach or negligence in connection with this Agreement to a maximum sum equal to
the total Costs payable by the Sponsor to Leicester under the Agreement or £100,000 whichever is the greater;

 

		13.5.2	in relation to liability outside the scope of Clause 13.5.1 , to £100,000.

 

		13.6	Subject to Clause 13.2 of this Agreement and excluding Sponsor’s indemnification obligations under Clause 13.1, Sponsor’s
total liability for any claims, losses, damages or expenses whatsoever and howsoever caused (even if caused by Sponsor’s
negligence and/or breach of contract) shall be limited for each event or series of linked events as follows:

 

		13.6.1	in relation to liability arising out of a breach or negligence in connection with this Agreement to a maximum sum equal to
the total Costs payable by the Sponsor to the injured Party under the Agreement or £100,000 whichever is the greater;

 

		13.6.2	in relation to liability outside the scope of Clause 13.6.1, to £100,000.

 

		13.7	Whilst Glasgow and Leicester will use all reasonable endeavours to ensure the accuracy of the work performed and any information
and Results given, Glasgow and Leicester make no warranty, express or implied, as to accuracy and, subject to Clause 13.2
will not be held responsible for any consequence arising out of any inaccuracies or omissions unless such inaccuracies or omissions
are the result of Glasgow’s and/or Leicester’s negligence.

 

		13.8	The Sponsor acknowledges that the nature of the Project is research based and the application of any Results will not be thoroughly
tested. Accordingly, subject to Clause 2, Glasgow and Leicester will not be liable for any claims, losses, damages or expenses
whatsoever and howsoever caused arising out of any use (or interpretation) by the Sponsor or any other party of the Results (or
any product or process generated out of them), notwithstanding that the formulation of such product or process may be based upon
the Results.

 

		13.9	The Sponsor warrants to Leicester and Glasgow that it has effected and shall maintain for the period of this Agreement and
thereafter at all times during which the Sponsor is making use of developing and/or commercially exploiting the Arising IP, insurance
in a minimum of £500,000 Sterling to cover the loss, liability and damage outlined in Clause 13.1. The Sponsor shall at any
time upon demand produce to Leicester or Glasgow proof that this insurance has been affected and is in force. If Leicester or Glasgow
becomes aware that the Sponsor has failed to effect and/or maintain the insurance required under this Clause the University may
effect and maintain this insurance and the Sponsor shall be bound to reimburse Glasgow for the cost of effecting and maintaining
this insurance on demand.

 

		13.10	Each Party agrees that if it is notified by any third party of any claim or potential claim arising as a result of or in connection
with the Project or the Sponsor’s use development and/or commercial exploitation of the Arising IP, it shall:

 

    	- 9 -

    	 

    

 

Portions herein identified by [*****] have been omitted pursuant
to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of
this document has been filed separately with the Securities and Exchange Commission.

 

		13.10.1	forthwith inform the other Parties of such claim or potential claim;

 

		13.10.2	take all reasonable steps to prevent judgement by fault or by default being granted in favour of
that third party;

 

		13.10.3	ensure that the other Parties are given the right to conduct proper consultations with the third
party in relation to the claim or potential claim; and

 

		13.10.4	if appropriate, allow the other Parties to join in the defence (including, but not limited to,
settlement litigation or appeal) of any such claim.

 

If reasonably
requested by a Party the defence to any such claim will be jointly conducted by the Parties. Notwithstanding anything to the contrary
in this Section 13.10, to the extent any claim or potential claim by a third party is related solely to the use, development and/or
commercial exploitation of the Arising IP independent of Glasgow’s or Leicester’s Background IP, then Sponsor shall
have the sole and exclusive right to defend any such claim or potential claim, and Glasgow and Leicester shall provide Sponsor
reasonable cooperation, at Sponsor’s expense, in connection therewith.

 

		14	Third Party Rights

 

		14.1	The Parties to this Agreement do not intend that any of its terms will be enforceable by virtue of the Contracts (Rights of
Third Parties) Act 1999 by any person not a Party to it.

 

		15	Entire Agreement

 

		15.1	Each Party acknowledges that this Agreement contains the whole agreement between the Parties in respect of its subject matter
and supersedes all prior arrangements, agreements and understandings between them relating to the subject matter.

 

		16	Force Majeure

 

		16.1	Any failure or delay by any Party in the performance of its obligations pursuant to this Agreement which is due to a force
majeure event will not be deemed a default of this Agreement or a ground for termination.

 

		17	Assignment

 

		17.1	This Agreement shall not be assigned by any Party without the prior written consent of the other Parties, such consent not
to be unreasonably withheld or delayed. Notwithstanding the foregoing, Sponsor may assign this Agreement in connection with any
merger, consolidation or sale of all or substantially all of the assets of Sponsor to which this Agreement relates.

 

		18	Variation

 

		18.1	Any variation to this Agreement (and/or the Project) shall be in writing and signed by authorised signatories for all Parties.

 

    	- 10 -

    	 

    

 

Portions herein identified by [*****] have been omitted pursuant
to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of
this document has been filed separately with the Securities and Exchange Commission.

 

		19	Severability

 

		19.1	If any provision of this Agreement is declared void or unenforceable, such provision shall be severed from this Agreement,
which shall otherwise remain in full force and effect.

 

		20	Waiver

 

		20.1	No failure, delay relaxation or indulgence on the part of any Party in exercising or partial exercise of any right hereunder
shall operate as a waiver of such rights.

 

		21	Notices

 

		21.1	Any notice, demand or communication in connection with this Agreement will be in writing and may be delivered by hand, first
class post, Special Delivery post but not by email addressed to the recipients below (or another person which the recipients have
notified in writing to the sender in accordance with this Clause 21.1, to be received by the sender not less than seven days
before the notice is despatched).

 

		21.1.1	For Leicester – to Enterprise and Business Development Office, University of Leicester, University Road, Leicester, LE1
7RH, United Kingdom

 

		21.1.2	For Glasgow – to Head of Legal, Research, Support Office, University of Glasgow, Room 404, 10, The Square, Glasgow, G12
8QQ

 

		21.1.3	For the Sponsor – to Philip J Young, CEO, AmpliPhi Biosciences, 4870 Sadler Rd Suite 300, Glen Allen, VA 23060, USA.                       

 

		21.2	The notice, demand or communication will be deemed to have been duly served:

 

		21.2.1	if delivered by hand, at the time of delivery;

 

		21.2.2	if delivered by first class post or Special Delivery post, 48 hours after being posted (excluding days other than business
days in England).

 

		21.3	The contacts for academic issues and day to day management of the Project will be:-

 

		21.3.1	For Leicester:- Dr Martha Clokie, Dept Infection, Immunity & Inflammation, University of Leicester, Maurice Shock Medical
Sciences Building, University Road, Leicester, LE1 9HN, United Kingdom

 

		21.3.2	For Glasgow:- Dr Gill Douce, Institute of infection, Immunity and Inflammation, MVLS, Glasgow Biomedical Research Centre, University
Place, University of Glasgow, Glasgow, G12 8TA, United Kingdom.

 

		21.3.3	For the Sponsor:- Philip J Young, CEO, AmpliPhi Biosciences, 800 E. Leigh St, Richmond, VA 23219, USA.

 

		22	Disputes

 

		22.1	All disputes will initially be referred by a Party to a representative of each Party responsible for the overall performance
of this Agreement, who will meet as soon as reasonably practicable to discuss the dispute. If those representatives are unable
to resolve the dispute after meeting, the dispute shall be referred to the Managing Director of the Sponsor and Head of Legal of
Glasgow in disputes relating to programme of work and to the Head of Technology Transfer of Leicester for disputes relating to
the role of Project Coordinator. The Directors will meet within 20 working days and attempt to resolve the dispute.

 

    	- 11 -

    	 

    

 

Portions herein identified by [*****] have been omitted pursuant
to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of
this document has been filed separately with the Securities and Exchange Commission.

 

		22.2	If any dispute arises out of this Agreement which the Directors are unable to resolve within 5 working days of their meeting
pursuant to Clause 22.1, the Parties will attempt to settle it by mediation in accordance with the Centre for Dispute Resolution
(CEDR) Model Mediation Procedure.

 

		22.3	To initiate a mediation a Party must give notice in writing to the other Parties requesting a mediation (the ‘ADR Notice’)
and send a copy of the ADR Notice to CEDR.

 

		22.4	If there is any point in the conduct of the mediation (including nomination of the mediator) upon which the Parties cannot
agree within 14 days from the date of the ADR Notice, CEDR will, at the request of any Party, decide that point for the Parties,
having consulted with them.

 

		22.5	The mediation will start not later than 28 days after the date of the ADR Notice.

 

		22.6	No Party may commence any court proceedings in relation to any dispute arising out of this Agreement until they have attempted
to settle it by mediation and such attempt has been unsuccessful, provided that nothing in this Agreement will prevent a Party
seeking injunctive relief to prevent or stay a breach of any provision of this Agreement.

 

		23	Governing Law

 

		23.1	This Agreement is governed by English law and the Parties submit to the exclusive jurisdiction of the courts of England and
Wales.

 

    	- 12 -

    	 

    

 

Portions herein identified by [*****] have been omitted pursuant
to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of
this document has been filed separately with the Securities and Exchange Commission.

 

Annex
1

 

The Project

 

‘Use
of Hamster and mouse models of C. difficile infection to provide further

validation
of the use of bacteriophage in the treatment of C. difficile

infections’

 

Glasgow’s
contribution to the Project

 

Project
program

 

[*****]

 

Leicester’s
contribution to the Project

 

Leicester will provide Leicester’s C. difficile specific
bacteriophage for testing in Glasgow’s animal models of infection.

 

Leicester will also fulfil the role of Project Coordinator;
including scheduling regular Project updates and meetings, collating data and submitting reports to Sponsor.

 

Sponsor’s
contribution to the Project

 

In addition to funding the work, Sponsor will provide advice
throughout the project through regular telecons, e-mails and meetings.

 

    	- 13 -

    	 

    

 

Portions herein identified by [*****] have been omitted pursuant
to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of
this document has been filed separately with the Securities and Exchange Commission.

 

Annex
2

 

Financial

 

[*****]

 

    	- 14 -

    	 

    

 

Portions herein identified by [*****] have been omitted pursuant
to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of
this document has been filed separately with the Securities and Exchange Commission.

 

	Signed	 	 	Signed	 
	 	 	 	 	 
	Authorised Signature for and on behalf of Sponsor	 	Authorised Signature for and on behalf of Glasgow
	 	 	 	 	 
	Name	Philip J. Young	 	Name	 
	 	 	 	 	 
	Position	President & CEO	 	Position	 
	 	 	 	 	 
	Dated	 	 	Dated	 
	 	 	 	 	 
	Signed	 	 	 	 
	 	 	 	 	 
	Authorised Signature for and on behalf of Leicester	 	 	 
	 	 	 	 	 
	Name	Dr Chris Jones	 	 	 
	 	 	 	 	 
	Position	Head of Research Commercialisation	 	 	 
	 	 	 	 	 
	Dated	 	 	 	 

 

    	- 15 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00224-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00224-of-00352.parquet"}]]